Videos

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses how to classify symptom severity, assess control, and monitor therapy for asthma and chronic obstructive pulmonary disorder.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the role pharmacists can play in helping physicians interpret urine screens.

Dennis Williams, PharmD, FAPhA, discusses the current management strategies for allergic rhinitis.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the problems related to inappropriate equianalgesic conversions when performing opioid rotations.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses the current guidelines pharmacists should refer to when selecting respiratory medication inhalers and managing asthma and chronic obstructive pulmonary disorder.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Daniel T. Abazia, PharmD, BCPS, discusses some of the non-pharmacologic treatment options that pharmacists can recommend to patients experiencing opioid-induced constipation.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses and debunks the myths and hysteria surrounding the use of opioid therapy in treating non-cancer pain.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses strategies pharmacists can employ to enhance the safe use of chronic opioid therapy.

Daniel T. Abazia, PharmD, BCPS, outlines some of the factors that might contribute to a patient's propensity to experience opioid-induced constipation.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the effects of expanded naloxone access.

Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, professor and department chair for Pharmacy Practice, University of Mississippi School of Pharmacy, explains why obesity is considered a chronic disease.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, offers tips for how pharmacists can monitor for hypoglycemia in type 2 diabetics on second-line therapies.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the obstacles that pharmacists are encountering as naloxone access continues to improve.

Dennis Williams, PharmD, FAPhA, talks about ways to prevent allergies related to pets and dust.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, outlines some strategies for pharmacists tasked with selecting the most appropriate second-line therapy for their patients with type 2 diabetes.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what comorbid conditions to look out for among asthma and COPD patients.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the challenges that pharmacists face when treating behavioral health conditions.

Sneha Srivastava, PharmD, BCACP, discusses how pharmacists can work toward improving outcomes for patients recently discharged after heart failure.

Sneha Srivastava, PharmD, BCACP, discusses the new and emerging therapies to treat heart failure.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses whether or not allowing pharmacists to dispense naloxone without a prescription can help reduce fatal outcomes.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses how pharmacists can combat the stigmas associated with mental illness.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what therapeutic options are available for managing asthma and chronic obstructive pulmonary disorder.

Sneha Srivastava, PharmD, BCACP, describes the role of the pharmacist at the time of discharge for heart failure patients.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses how pharmacists can promote behavioral health in their daily practice.

Dan Benamoz, RPh, President and CEO of Pharmacy Development Services, discusses how independent pharmacists can improve their bottom line.

Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, professor and department chair for Pharmacy Practice, University of Mississippi School of Pharmacy, outlines some risk factors for obesity.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.

Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the roles that pharmacists can play on interdisciplinary health care teams.